Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis-Reference-Cited by-同舟云学术

Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis

Published:2018-06 Issue:11 Volume:197 Page:1410-1420
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Chalmers James D.¹,Aliberti Stefano²³,Filonenko Anna⁴,Shteinberg Michal⁵,Goeminne Pieter C.⁶⁷,Hill Adam T.⁸⁹,Fardon Thomas C.¹,Obradovic Dusanka¹⁰,Gerlinger Christoph⁴¹¹,Sotgiu Giovanni¹²,Operschall Elisabeth⁴,Rutherford Robert M.¹³,Dimakou Katerina¹⁴,Polverino Eva¹⁵,De Soyza Anthony¹⁶¹⁷,McDonnell Melissa J.¹³¹⁷

Affiliation:

1. Scottish Centre for Respiratory Research, University of Dundee, Dundee, United Kingdom

2. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

3. Internal Medicine Department, Respiratory Unit, and Cystic Fibrosis Adult Center, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

4. Bayer AG, Berlin, Germany

5. Pulmonary Institute, Carmel Medical Center, Haifa, Israel

6. Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium

7. Respiratory Disease, AZ Nikolaas, Sint-Niklaas, Belgium

8. Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

9. University of Edinburgh, Edinburgh, United Kingdom

10. Institute for Pulmonary Diseases of Vojvodina Sremska Kamenica and Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

11. Gynecology, Obstetrics, and Reproductive Medicine, University of Saarland Medical School, Homburg/Saar, Germany

12. Clinical Epidemiology and Medical Statistics Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy

13. Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland

14. 5th Department of Pulmonary Medicine, “Sotiria” Chest Diseases Hospital, Athens, Greece

15. Servei de Pneumologia, Hospital Clinic, Institut D’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedade Respiratorias (CIBERES), Barcelona, Spain

16. Adult Bronchiectasis Service and Sir William Leech Centre for Lung Research, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Heaton, United Kingdom; and

17. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201711-2202OC

Reference41 articles.

1. Management of bronchiectasis in adults

2. Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study

3. European Respiratory Society guidelines for the management of adult bronchiectasis

4. Diagnóstico y tratamiento de las bronquiectasias

5. British Thoracic Society guideline for non-CFbronchiectasis

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nebulized hypertonic saline and positive expiratory pressure device use in patients with bronchiectasis: Analysis from the United States Bronchiectasis and NTM research registry;Respiratory Medicine and Research;2024-11

2. Current physiotherapy practice for adults with bronchiectasis: Data from the Australian bronchiectasis registry;Respiratory Medicine;2024-11

3. Culture-independent Multilocus sequence typing screening for Haemophilus influenzae cross-infection in non-cystic fibrosis bronchiectasis;Diagnostic Microbiology and Infectious Disease;2024-09

4. The roles of bacteria and viruses in COPD-Bronchiectasis association: A prospective cohort study;Respiratory Medicine;2024-09

5. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months;The Lancet Respiratory Medicine;2024-09